Research programme: drug discovery - Evotec AG/Institute of Medical Technology Magdeburg/KeyNeurotek AG

Drug Profile

Research programme: drug discovery - Evotec AG/Institute of Medical Technology Magdeburg/KeyNeurotek AG

Latest Information Update: 16 Oct 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute of Medical Technology Magdeburg; KeyNeurotek AG
  • Developer Evotec AG; Institute of Medical Technology Magdeburg; KeyNeurotek Pharmaceuticals AG
  • Class Small molecules
  • Mechanism of Action Aminopeptidase inhibitors; Dipeptidyl-peptidase and tripeptidyl-peptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical CNS disorders; Immunological disorders; Metabolic disorders; Skin disorders

Most Recent Events

  • 15 Oct 2009 This programme is still in active development
  • 14 Jan 2003 Preclinical trials in CNS disorders in Germany (unspecified route)
  • 14 Jan 2003 Preclinical trials in Immunological disorders in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top